Gina Chapman

CIK: 0001989220

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)2 (28.6%)

Position reduction

Option Exercises (M)2 (28.6%)

Derivative conversions

Awards (A)3 (42.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TRDA

Entrada Therapeutics, Inc.

Director

CRGX

CARGO Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

TRDA
Entrada Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
TRDA
Entrada Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
19K shares-
CRGX
CARGO Therapeutics, Inc.
Mar 14, 2025
Award(A)
Direct
200K shares-
CRGX
CARGO Therapeutics, Inc.
Sep 19, 2024
Exercise(M)
Direct
3K shares at avg. $5.03$15K
CRGX
CARGO Therapeutics, Inc.
Sep 19, 2024
Sale(S)
Direct
3K shares at avg. $25.03$74K
CRGX
CARGO Therapeutics, Inc.
Sep 18, 2024
Sale(S)
Direct
7.2K shares at avg. $25.09$180K
CRGX
CARGO Therapeutics, Inc.
Sep 18, 2024
Exercise(M)
Direct
7.2K shares at avg. $5.03$36K

		Type	Shares	Price		Ownership
Jun 10, 2026	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
Jun 11, 2025	TRDA Entrada Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	19,000	-	-	Direct
Mar 14, 2025	CRGX CARGO Therapeutics, Inc.	Award(A)	200,000	-	-	Direct
Sep 19, 2024	CRGX CARGO Therapeutics, Inc.	Exercise(M)	2,975	$5.03	$14,964	Direct
Sep 19, 2024	CRGX CARGO Therapeutics, Inc.	Sale(S)	2,975	$25.03	$74,457	Direct
Sep 18, 2024	CRGX CARGO Therapeutics, Inc.	Sale(S)	7,166	$25.09	$179,775	Direct
Sep 18, 2024	CRGX CARGO Therapeutics, Inc.	Exercise(M)	7,166	$5.03	$36,045	Direct

1-7 of 7 transactions

About Chapman Gina

Chapman Gina (SEC CIK 0001989220) files insider reports with the SEC as Director of Entrada Therapeutics, Inc. (TRDA) and President & CEO of CARGO Therapeutics, Inc. (CRGX).

Signal8 holds 4 ownership filings by Chapman Gina, all Form 4s, filed between Sep 20, 2024 and Jun 12, 2026. Those filings report 7 transactions, from Sep 18, 2024 to Jun 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Chapman Gina's filings is in BOSTON, MA.

Recent filings by Chapman Gina

Jun 10, 2026: Grant or award of TRDA derivative securities (Form 4, code A).
Jun 11, 2025: Grant or award of TRDA derivative securities (Form 4, code A).
Mar 14, 2025: Grant or award of CRGX shares (Form 4, code A).
Sep 19, 2024: Option exercise of CRGX shares (Form 4, code M).
Sep 19, 2024: Open-market sale of CRGX shares (Form 4, code S).

Other insiders filing for Entrada Therapeutics, Inc. (TRDA)

MPM BIOVENTURES 2018, L.P., 10% Owner
MPM BioVentures 2014, L.P., 10% Owner
Doshi Dipal, CEO
Dowden Nathan J, President & COO
Sethuraman Natarajan, President, Research & Develop.
WENTWORTH KORY JAMES, Chief Financial Officer

How to read Form 4 transaction codes